LIVIVO - Search results -

Search results

Result 1 - 10 of total 19

Search options

Article ; Online: Hematologic Manifestations of Parvovirus B19 Infection.

Algwaiz, Ghada / Alharbi, Abrar / Alsehaim, Khuloud / Alahmari, Ali / El Fakih, Riad / Aljurf, Mahmoud

Hematology/oncology and stem cell therapy

2023 Volume 16, Issue 4, Page(s) 316–322

Abstract: Parvovirus B19 virus infection is widespread among humans because of its highly infectious and obstinate nature, with up to 80% of the population testing positive for IgG antibodies against the virus. Pronormoblasts observed in biopsy are the hallmarks ... ...

Abstract	Parvovirus B19 virus infection is widespread among humans because of its highly infectious and obstinate nature, with up to 80% of the population testing positive for IgG antibodies against the virus. Pronormoblasts observed in biopsy are the hallmarks of PVB19 infection. In addition, PVB19 affects the skin, heart, brain, joints, and liver and can be diagnosed through antibody detection or DNA detection via PCR. Due to its capsid proteins' high affinity for bone marrow receptors, its main presentation is the suppression of bone marrow functions. It has been shown to affect patients with hemolytic anemia and patients with hematological malignancies, presenting with pure red cell aplasia. The main available effective treatment option is IV immunoglobulins; however, the risk of recurrence remains high after treatment.
MeSH term(s)	Humans ; Erythema Infectiosum/complications ; Erythema Infectiosum/pathology ; Bone Marrow/pathology ; Red-Cell Aplasia, Pure/therapy ; Parvovirus B19, Human/genetics ; Parvoviridae Infections/complications
Language	English
Publishing date	2023-05-23
Publishing country	Saudi Arabia
Document type	Journal Article ; Review
ZDB-ID	2651893-4
ISSN	2589-0646 ; 1658-3876
ISSN (online)	2589-0646
ISSN	1658-3876
DOI	10.56875/2589-0646.1031
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6950: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Successful Recovery of COVID-19 Associated With Cardiomyopathy in Advanced Breast Cancer Patient With Pulmonary Lymphangitis Carcinomatosis.

Alquaydheb, Hisham / Alharbi, Abrar / Badran, Ahmed / Alshamsan, Bader / Algwaiz, Ghada / Elshenawy, Mahmoud A / Ajarim, Dahish

Clinical medicine insights. Case reports

2023 Volume 16, Page(s) 11795476231210142

Abstract: SARS-CoV-2 infection induces myocardiopathy in 19% of severe cases, with a mortality rate of up to 51%. The mainstay of treatment is supportive care, steroids, and tocilizumab (anti-IL-6). This is a case of a 43-year-old woman diagnosed with hormone- ... ...

Abstract	SARS-CoV-2 infection induces myocardiopathy in 19% of severe cases, with a mortality rate of up to 51%. The mainstay of treatment is supportive care, steroids, and tocilizumab (anti-IL-6). This is a case of a 43-year-old woman diagnosed with hormone-positive breast cancer with lung metastasis and pulmonary lymphangitis carcinomatosis (PLC). Her baseline cardiac function was within normal limits. She presented to the emergency department with respiratory distress. Chest CT showed multiple bilateral ground-glass opacities consistent with COVID-19 pneumonia and confirmed by COVID-19-PCR nasal swab. Her condition deteriorated, and she was urgently admitted to the intensive care unit with evidence of a cytokine storm. She was started on tocilizumab, dexamethasone, and meropenem. Echocardiogram (echo) showed a severely reduced ejection fraction with severe global hypokinesis. A second dose of tocilizumab was given, and the dexamethasone dose was increased. Fortunately, the patient had significant clinical and biochemical improvement and regained her normal cardiac function. In conclusion, dexamethasone and tocilizumab could be promising aids in treating cardiomyopathy secondary to SARS-CoV-2 infection.
Language	English
Publishing date	2023-12-06
Publishing country	United States
Document type	Case Reports
ZDB-ID	2580498-4
ISSN	1179-5476
ISSN	1179-5476
DOI	10.1177/11795476231210142
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Ribociclib-Induced Pneumonitis: A Case Report.

Algwaiz, Ghada / Badran, Ahmed Ali / Elshenawy, Mahmoud A / Al-Tweigeri, Taher

Breast care (Basel, Switzerland)

2020 Volume 16, Issue 3, Page(s) 307–311

Abstract: Background: Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have been a significant breakthrough in the management of hormone receptor-positive, HER2-negative metastatic breast cancer based on the results of several large phase III randomized trials. ... ...

Abstract	Background: Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have been a significant breakthrough in the management of hormone receptor-positive, HER2-negative metastatic breast cancer based on the results of several large phase III randomized trials. The most common reported toxicity is myelosuppression due to disease such as leukopenia, neutropenia, and thrombocytopenia. Other toxicities associated with CDK 4/6 inhibitors include mucositis, fatigue, gastrointestinal side effects, hepatic toxicities, and QTc prolongation. Despite a good toxicity profile in pivotal studies, the increased rates of use in clinical practice may show less prevalent but lethal toxicity such as lung injury. Case presentation: Here, we describe a female patient with metastatic hormone receptor-positive/human epidermal growth factor 2-negative breast cancer who developed lung toxicity while on ribociclib. Discussion: Lung injury is a possible side effect of CDK 4/6 inhibitors and there is an increasing need to understand the management of this side effect.
Language	English
Publishing date	2020-07-08
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2202236-3
ISSN	1661-3805 ; 1661-3791
ISSN (online)	1661-3805
ISSN	1661-3791
DOI	10.1159/000507647
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6620: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Lung Cancer in Saudi Arabia.

Jazieh, Abdul Rahman / Algwaiz, Ghada / Alshehri, Salem M / Alkattan, Khaled

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

2019 Volume 14, Issue 6, Page(s) 957–962

MeSH term(s)	Aged ; Early Detection of Cancer ; Female ; Humans ; Lung Neoplasms/epidemiology ; Male ; Registries ; Saudi Arabia/epidemiology
Language	English
Publishing date	2019-05-20
Publishing country	United States
Document type	Editorial ; Research Support, Non-U.S. Gov't
ZDB-ID	2432037-7
ISSN	1556-1380 ; 1556-0864
ISSN (online)	1556-1380
ISSN	1556-0864
DOI	10.1016/j.jtho.2019.01.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6664: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 652: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Successful Recovery of COVID-19 Associated With Cardiomyopathy in Advanced Breast Cancer Patient With Pulmonary Lymphangitis Carcinomatosis

Hisham Alquaydheb / Abrar Alharbi / Ahmed Badran / Bader Alshamsan / Ghada Algwaiz / Mahmoud A Elshenawy / Dahish Ajarim

Clinical Medicine Insights: Case Reports, Vol

2023 Volume 16

Abstract	SARS-CoV-2 infection induces myocardiopathy in 19% of severe cases, with a mortality rate of up to 51%. The mainstay of treatment is supportive care, steroids, and tocilizumab (anti-IL-6). This is a case of a 43-year-old woman diagnosed with hormone-positive breast cancer with lung metastasis and pulmonary lymphangitis carcinomatosis (PLC). Her baseline cardiac function was within normal limits. She presented to the emergency department with respiratory distress. Chest CT showed multiple bilateral ground-glass opacities consistent with COVID-19 pneumonia and confirmed by COVID-19-PCR nasal swab. Her condition deteriorated, and she was urgently admitted to the intensive care unit with evidence of a cytokine storm. She was started on tocilizumab, dexamethasone, and meropenem. Echocardiogram (echo) showed a severely reduced ejection fraction with severe global hypokinesis. A second dose of tocilizumab was given, and the dexamethasone dose was increased. Fortunately, the patient had significant clinical and biochemical improvement and regained her normal cardiac function. In conclusion, dexamethasone and tocilizumab could be promising aids in treating cardiomyopathy secondary to SARS-CoV-2 infection.
Keywords	Medicine (General) ; R5-920
Subject code	616
Language	English
Publishing date	2023-12-01T00:00:00Z
Publisher	SAGE Publishing
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review.

Mohsen, Samiha / Sobash, Philip T / Algwaiz, Ghada Fahad / Nasef, Noor / Al-Zeidaneen, Safaa Abed / Karim, Nagla Abdel

Current oncology (Toronto, Ont.)

2022 Volume 29, Issue 3, Page(s) 1695–1708

Abstract: Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt's lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy ...

Abstract	Autophagy has been of novel interest since it was first demonstrated to have effect in Burkitt's lymphoma. Since that time, the autophagy agents chloroquine and hydroxychloroquine have become the only FDA (Food and Drug Administration)-approved autophagy inhibitors. While not approved for cancer therapy, there are ongoing clinical trials to evaluate their safety and efficacy. Pevonedistat has emerged as a novel inhibitor through the neddylation pathway and is an autophagy activator. This paper summarizes and presents current clinical trials for hydroxychloroquine (HCQ), chloroquine (CQ), and Pevonedistat for the clinician.
MeSH term(s)	Autophagy ; Chloroquine/pharmacology ; Chloroquine/therapeutic use ; Humans ; Hydroxychloroquine/pharmacology ; Hydroxychloroquine/therapeutic use ; Neoplasms/drug therapy ; United States
Chemical Substances	Hydroxychloroquine (4QWG6N8QKH) ; Chloroquine (886U3H6UFF)
Language	English
Publishing date	2022-03-05
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol29030141
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4305: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Lung transplantation outcomes in underweight recipients: A single center experience.

Abdulqawi, Rayid / Saleh, Rana Ahmed / Devol, Edward / Aldakhil, Haifa / Saleh, Waleed / Hashim, Mahmoud / Albogumi, Eid / Algwaiz, Ghada / Khalid, Mohammed / Al-Mutairy, Eid Abdullah

Heliyon

2023 Volume 9, Issue 4, Page(s) e15080

Abstract: Background: Current guidelines recommend a body mass index (BMI) of 16 kg/m: Methods: This retrospective observational study included adult lung transplant recipients who underwent transplantation for the first time between March 2010 and March 2022 ... ...

Abstract	Background: Current guidelines recommend a body mass index (BMI) of 16 kg/m Methods: This retrospective observational study included adult lung transplant recipients who underwent transplantation for the first time between March 2010 and March 2022 at King Faisal Specialist Hospital and Research Center and excluded patients with obesity. We defined an underweight status as a BMI <17 kg/m Results: Forty-eight of the 202 lung transplant recipients were underweight at the time of surgery. The underweight patients had similar lengths of hospital (p = 0.53) and intensive care unit (p = 0.81) stays compared to other patients. Thirty-three percent of underweight patients had died within 5-year follow-up, compared to 34% of patients who were not underweight. There was no significant difference in mortality risk between underweight patients and patients with normal BMIs in our multivariable Cox regression model (adjusted HR 1.57, 95%CI: 0.77-3.20, p = 0.21). Exploratory analyses revealed that a pre-transplant BMI <13 kg/m Conclusions: Our findings suggest that patients with BMIs of 13-17 kg/m
Language	English
Publishing date	2023-04-01
Publishing country	England
Document type	Journal Article
ZDB-ID	2835763-2
ISSN	2405-8440
ISSN	2405-8440
DOI	10.1016/j.heliyon.2023.e15080
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Do Multidisciplinary Tumor Board Discussions Correlate With Increase in 5-Year Survival? A Meta-Analysis Study

Ghada Algwaiz / Yezan Salam / Rami Bustami / Mazen Ferwana / Abdul Rahman Jazieh

Global Journal on Quality and Safety in Healthcare, Pp 3-

2021 Volume 10

Abstract: Introduction: Due to the complex nature of cancer cases, it is imperative that the involved healthcare providers coordinate the patients care plan in union to reach the best possible outcome in the smoothest and fastest manner. This is what ... ...

Abstract	Introduction: Due to the complex nature of cancer cases, it is imperative that the involved healthcare providers coordinate the patients care plan in union to reach the best possible outcome in the smoothest and fastest manner. This is what multidisciplinary tumor board (MTB) meetings strive to achieve. Conducting regular MTB meetings requires significant investment of time and finances. It is thus vital to assess the empirical benefits of such practice. Methods: A meta-analysis was conducted to evaluate the literature regarding the impact of MTB meetings on patient 5-year survival. Relevant studies were identified by searching Ovid MEDLINE and Embase databases from January 1995 to July 2019. Studies were included if they assessed 5-year survival in cases discussed in MTB meetings and used a comparison group and/or a pretest and posttest design. Results: Five articles met the study's inclusion criteria. Quality of studies was affected by selection bias and the use of historic cohorts. The results showed significantly improved 5-year survival in the MTB group compared with the non-MTB groups (odds ratio for 5-year death rate of 0.59, CI 0.45–0.78, p < 0.001). Conclusion: This meta-analysis showed that cancer MTB meetings have a significant impact on patients’ 5-year survival. This could be because of several reasons, such as less time to treatment initiation, better adherence to guidelines, higher numbers of investigational imaging, lesser surgical complications, and recurrence rates. Future prospective studies are needed to further delineate reasons for improvement of outcome to enhance the benefits of this approach.
Keywords	tumor board ; multidisciplinary care ; 5-year survival ; patient-oriented outcome ; multidisciplinary tumor board meetings ; Medicine (General) ; R5-920
Subject code	616
Language	English
Publishing date	2021-02-01T00:00:00Z
Publisher	Innovative Healthcare Institute
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Do Multidisciplinary Tumor Board Discussions Correlate With Increase in 5-Year Survival? A Meta-Analysis Study.

Algwaiz, Ghada / Salam, Yezan / Bustami, Rami / Ferwana, Mazen / Jazieh, Abdul Rahman

Global journal on quality and safety in healthcare

2020 Volume 4, Issue 1, Page(s) 3–10

Abstract	Introduction: Due to the complex nature of cancer cases, it is imperative that the involved healthcare providers coordinate the patients care plan in union to reach the best possible outcome in the smoothest and fastest manner. This is what multidisciplinary tumor board (MTB) meetings strive to achieve. Conducting regular MTB meetings requires significant investment of time and finances. It is thus vital to assess the empirical benefits of such practice. Methods: A meta-analysis was conducted to evaluate the literature regarding the impact of MTB meetings on patient 5-year survival. Relevant studies were identified by searching Ovid MEDLINE and Embase databases from January 1995 to July 2019. Studies were included if they assessed 5-year survival in cases discussed in MTB meetings and used a comparison group and/or a pretest and posttest design. Results: Five articles met the study's inclusion criteria. Quality of studies was affected by selection bias and the use of historic cohorts. The results showed significantly improved 5-year survival in the MTB group compared with the non-MTB groups (odds ratio for 5-year death rate of 0.59, CI 0.45-0.78, Conclusion: This meta-analysis showed that cancer MTB meetings have a significant impact on patients' 5-year survival. This could be because of several reasons, such as less time to treatment initiation, better adherence to guidelines, higher numbers of investigational imaging, lesser surgical complications, and recurrence rates. Future prospective studies are needed to further delineate reasons for improvement of outcome to enhance the benefits of this approach.
Language	English
Publishing date	2020-12-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	3000738-0
ISSN	2589-9449 ; 2666-2353
ISSN (online)	2589-9449
ISSN	2666-2353
DOI	10.36401/JQSH-20-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Lung transplantation outcomes in underweight recipients: A single center experience

Abdulqawi, Rayid / Saleh, Rana Ahmed / Devol, Edward / Aldakhil, Haifa / Saleh, Waleed / Hashim, Mahmoud / Albogumi, Eid / Algwaiz, Ghada / Khalid, Mohammed / Al-Mutairy, Eid Abdullah

Heliyon. 20232023 Apr. 01, Apr. 01, v. 9, no. 4 p.e15080-

2023

Abstract: Current guidelines recommend a body mass index (BMI) of 16 kg/m² as the minimum threshold for lung transplantation, despite mixed evidence on outcomes in underweight patients. The current study aimed to describe survival outcomes of underweight patients ... ...

Abstract	Current guidelines recommend a body mass index (BMI) of 16 kg/m² as the minimum threshold for lung transplantation, despite mixed evidence on outcomes in underweight patients. The current study aimed to describe survival outcomes of underweight patients who underwent lung transplantation at a single center. This retrospective observational study included adult lung transplant recipients who underwent transplantation for the first time between March 2010 and March 2022 at King Faisal Specialist Hospital and Research Center and excluded patients with obesity. We defined an underweight status as a BMI <17 kg/m². Forty-eight of the 202 lung transplant recipients were underweight at the time of surgery. The underweight patients had similar lengths of hospital (p = 0.53) and intensive care unit (p = 0.81) stays compared to other patients. Thirty-three percent of underweight patients had died within 5-year follow-up, compared to 34% of patients who were not underweight. There was no significant difference in mortality risk between underweight patients and patients with normal BMIs in our multivariable Cox regression model (adjusted HR 1.57, 95%CI: 0.77-3.20, p = 0.21). Exploratory analyses revealed that a pre-transplant BMI <13 kg/m² was associated with a trend towards increased 5-year mortality (adjusted HR 4.00, 95%CI: 0.87-18.35, p = 0.07). Our findings suggest that patients with BMIs of 13-17 kg/m² may be candidates for lung transplantation. Large multi-center cohort studies are needed to confirm the lower BMI limit for safely transplanting patients.
Keywords	adults ; body mass index ; hospitals ; lungs ; mortality ; obesity ; observational studies ; regression analysis ; risk ; surgery ; underweight ; Lung transplantation outcomes ; BM
Language	English
Dates of publication	2023-0401
Publishing place	Elsevier Ltd
Document type	Article ; Online
Note	Use and reproduction
ZDB-ID	2835763-2
ISSN	2405-8440
ISSN	2405-8440
DOI	10.1016/j.heliyon.2023.e15080
Database	NAL-Catalogue (AGRICOLA)

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito